{"aliases":[{"type":"Synonym","name":"PARP inhibitor AZD2281"},{"type":"CodeName","name":"AZD2281"},{"type":"CodeName","name":"KU-0059436"},{"type":"USBrandName","name":"Lynparza"},{"type":"CASRegistryName","name":"763113-22-0"},{"type":"CodeName","name":"AZD 2281"},{"type":"CodeName","name":"AZD-2281"},{"type":"ForeignBrandName","name":"Olanib"},{"type":"ForeignBrandName","name":"Olaparix"}],"definition":{"html":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","text":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/olaparib","text":"Olaparib"},"nciConceptId":"C71721","nciConceptName":"Olaparib","termId":560191,"name":"olaparib","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"olaparib"}